Direct answer
Magnesium is an essential nutrient, but no universal best supplement form is established by the evidence reviewed here. Citrate absorbs better than oxide in small studies; specific magnesium laxatives can treat constipation. Blood-pressure effects are small, migraine prevention has limited evidence, and sleep benefits remain uncertain. The adult 350 mg supplemental/medicine UL excludes food and is not a safety guarantee; renal impairment and medicine-specific spacing need individual advice.
- Magnesium is an essential nutrient. Specific laxative products treat constipation; a 34-trial meta-analysis found a small average systolic blood-pressure reduction of about 2 mmHg. Migraine-prevention evidence is limited and treatment doses may require medical supervision. NIH ODS; Zhang et al., Hypertension.
- Sleep, anxiety, depression, diabetes and bone supplement findings are uncertain or mixed; older-adult idiopathic cramp evidence indicates little meaningful benefit — a systematic review found only 3 low-quality RCTs (151 participants) for insomnia (Mah & Pitre 2021).
- No universal best routine form is established by the studies reviewed here. Citrate has better absorption evidence than oxide, while oxide and citrate can have laxative uses. Glycinate is not established as the best-tolerated option. NIH ODS; Walker et al..
- Adult tolerable upper intake level from supplements and medicines: 350 mg/day for adults (NIH ODS Tolerable Upper Intake Level — food sources are excluded; this is not a safety guarantee and supervised treatment may differ).
- Some medicines need spacing from magnesium; diuretics and long-term PPIs can change magnesium status. Kidney impairment increases toxicity risk. Ask a pharmacist about the specific medicine and magnesium product. NIH ODS.
- Evidence grades: Strong for basic nutritional physiology; Moderate for selected clinical uses; Weak or Insufficient for several supplement claims.
Magnesium is essential for nerve, muscle, energy and bone functions. Correcting inadequate intake is distinct from treating symptoms. Specific magnesium laxatives can relieve constipation; blood-pressure trials show small average reductions, and migraine prevention requires an individual treatment plan. Sleep, anxiety, depression, glucose control and fracture-prevention claims remain uncertain. Citrate absorbs better than oxide in small studies, but the evidence reviewed here does not establish glycinate as the best-tolerated routine choice. Kidney disease, high doses and interacting medicines require particular care (NIH Office of Dietary Supplements; Form comparison).
Table of contents
- Evidence summary
- What magnesium is
- Selected magnesium forms
- How magnesium works
- What works and what does not
- Benefits with evidence grades
- Risks and reported side effects
- Selected interactions and precautions
- Who should avoid magnesium
- Dosage and how to take magnesium
- Infographics with full text versions
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict check | Strength |
|---|---|---|---|---|
| Magnesium is essential, but serum magnesium is an imperfect status marker. | NIH fact sheet summarizing physiology, intake, status assessment, and safety. | NIH ODS Magnesium Fact Sheet | NIH ODS public guidance; complete page-author declarations and every underlying-study financial chain are not supplied. | Strong |
| Citrate, chloride, lactate, and aspartate are generally more bioavailable than oxide or sulfate. | NIH summary, small human absorption studies and a 14-study review; absorption differences do not establish a clinical winner or universal GI tolerance advantage. | NIH ODS; Lindberg et al.; Pardo et al. (2021) | Lindberg: three NIH grants indexed; complete original conflicts/product terms not recovered. Pardo: no known financial or personal conflicts declared; full review funding and underlying-trial finances not recovered. | Moderate |
| Sleep benefits remain uncertain; deficient-vs-replete response differences are not established. | Older-adult studies used oxide/citrate, not glycinate; the small pooled evidence was low or very low certainty. NCCIH’s January 2024 summary predates newer trials. | Abbasi et al.; Mah & Pitre systematic review; NCCIH | Abbasi: Shahid Beheshti university institute support, no conflicts declared; product terms unreported. Mah/Pitre: no specific review grant, named graduate support and no conflicts declared. Underlying-study finance is not fully cleared. NCCIH is public guidance. | Weak |
| Magnesium-L-threonate has preliminary, industry-linked sleep findings. | A 2024 trial analyzed 76 adults over 3 weeks using 1 g MgT (75 mg elemental). Some questionnaire/wearable scores improved; total sleep time, overall Oura score and sleep efficiency did not differ significantly. | Hausenblas et al. MgT RCT | AIDP funded the trial; three authors had AIDP affiliations/study roles. Threotech manufactured and supplied Magtein; exact payment or donation terms were not stated. | Weak |
| Blood pressure lowering is real but modest. | Meta-analysis of 34 randomized double-blind placebo-controlled trials found small average BP reductions. | Zhang et al. Hypertension meta-analysis | IU Health–IU School of Medicine Strategic Research Initiative supported the review; authors declared no conflicts. Complete financing of all 34 trials was not traced. | Moderate |
| Magnesium oxide and citrate can work as osmotic laxatives. | Magnesium oxide clinical trials and the Japanese constipation guideline support osmotic laxatives; the citrate label covers occasional constipation, not routine nutritional dosing. | Magnesium oxide review; 2023 constipation guideline; DailyMed magnesium citrate label | Magnesium oxide review: AMED/JSPS support and multiple pharma relationships. Guideline committee: extensive company ties; full cash financing not specified. The guideline gives osmotic laxatives a strong recommendation/evidence A; the financial disclosures do not themselves change that stated grade. | Moderate |
| Magnesium is unlikely to meaningfully prevent idiopathic muscle cramps in older adults. | Cochrane review found magnesium unlikely to provide clinically meaningful cramp prophylaxis in older adults; pregnancy evidence remains uncertain. | Cochrane muscle cramps review | CIHR stipend, NIHR infrastructure, MRC centre and Motor Neurone Disease Association support were listed. An author wrote an included trial; another included trial had active manufacturer involvement. All trial finances were not fully traced. | Moderate |
| Migraine prevention may help some adults; treatment doses can exceed the population UL. | The 2018 review rated magnesium Grade C, possibly effective. NIH separately reports a historical 2012 AAN/AHS probably-effective recommendation. | von Luckner & Riederer systematic review; NIH ODS migraine summary | The 2018 review’s complete original funding, author conflicts and product terms were not recovered; NIH public guidance does not clear its underlying studies. | Moderate |
| Diabetes and blood sugar claims are mixed. | Simental-Mendia: overall HOMA-IR improved, but fasting glucose, HbA1c and insulin did not significantly improve. Chua: overall glucose/HbA1c and low-magnesium subgroup findings were not significant. NIH calls the clinical evidence small and conflicting. | Simental-Mendía et al.; Chua et al., JAFES 2017 (indexed 2021); NIH ODS | Simental-Mendia: complete original funding/conflicts not recovered. Chua/Cinco/Paz-Pacheco: funding: none and no conflicts declared; underlying-trial finances not fully traced. | Weak |
| Bone health depends on adequate magnesium, but supplementation evidence is not strong. | Observational reviews associated higher intake with some BMD measures; they did not establish supplement-driven fracture prevention. | Groenendijk et al.; Farsinejad-Marj et al. | Groenendijk: Jaap Schouten Foundation grant JSF_SU_17_8 indexed; full original conflicts unrecovered. Farsinejad-Marj: Isfahan University Food Security Research Center support/grant 54545; publisher states conflicts: none. Underlying-study finances not fully traced. | Weak |
What magnesium is
Magnesium is a mineral electrolyte and enzyme cofactor, not a sedative or hormone. In the body, it participates in more than 300 enzyme systems involved in protein synthesis, muscle and nerve function, blood glucose control, blood pressure regulation, energy production, DNA/RNA synthesis, and antioxidant defenses (NIH Office of Dietary Supplements).
An adult body contains about 25 grams of magnesium, with roughly 50% to 60% in bone and most of the rest in soft tissues; less than 1% is in serum, so a normal serum result does not always prove optimal total-body magnesium status (NIH Office of Dietary Supplements). Normal serum magnesium is about 0.75 to 0.95 mmol/L, and hypomagnesemia is commonly defined below 0.75 mmol/L (NIH Office of Dietary Supplements).
The active compound — what actually does the work
The active nutrient is the magnesium ion, Mg2+. The attached compound — glycinate, citrate, oxide, malate, threonate, taurate, chloride, sulfate, orotate, or bisglycinate — mainly changes solubility, elemental magnesium percentage, GI tolerance, absorption pattern, price, and marketing claims.
Dietary magnesium versus supplemental magnesium
Food contributes to total magnesium intake. The supplemental/medicine UL excludes magnesium naturally present in food and drinks. This distinction does not establish that food magnesium is always absorbed more slowly than supplemental forms (NIH Office of Dietary Supplements).
Selected forms and clinical roles
The most important buying rule is to read the label for elemental magnesium, not the total compound weight. A tablet labeled “magnesium glycinate 2,000 mg” may not provide 2,000 mg elemental magnesium, because most of that weight is glycine plus mineral salt. NIH label guidance.
| Form | What it is | Bioavailability | Clinical role / practical limits | Price comparison | Verdict |
|---|---|---|---|---|---|
| Magnesium glycinate | Magnesium bound to glycine; often sold for sleep and calm. | The reviewed sources do not establish superior glycinate absorption or tolerability over every other salt. Bioavailability review; Small comparison trial. | Possible intake replacement if clinically indicated and tolerated; no established sleep-form preference. | — | No universal best routine form established; choose elemental dose and individual tolerance. |
| Magnesium bisglycinate | Magnesium chelated with two glycine molecules; practically overlaps with “glycinate” marketing. | No unique outcome or universal tolerance advantage is established by the sources reviewed here. | Intake replacement when indicated; medicine spacing depends on the specific medicine. | — | Check the exact ingredient and elemental dose; marketing labels alone do not establish equivalence or superiority. |
| Magnesium citrate | Magnesium salt of citric acid. | Good; citrate outperformed oxide in small human absorption studies and is listed by NIH among better-absorbed forms (Lindberg et al., NIH ODS). | Constipation, general supplementation when looser stools are acceptable. | — | Better absorbed than oxide in small studies; a specific citrate laxative can treat occasional constipation. |
| Magnesium oxide | Magnesium plus oxygen; high elemental magnesium by weight but poorly soluble. | Lower than citrate; NIH notes oxide is less bioavailable than more soluble forms (NIH ODS). | Osmotic laxative use has clinical evidence; nutrient absorption is lower than citrate. | — | Lower absorption; constipation trials support laxative efficacy. GI effects vary by dose and product. |
| Magnesium malate | Magnesium bound to malic acid. | No adequate malate-vs-oxide clinical absorption comparison was established in the reviewed sources. | Often marketed for energy and muscle pain. | Not systematically priced | Unique energy or muscle-pain benefits are not established by the sources reviewed here. |
| Magnesium L-threonate | Magnesium salt of L-threonic acid, marketed for brain penetration and sleep/cognition. | Animal/mechanistic rationale; human outcome evidence is early and product-linked. | Preliminary sleep evidence; no proven cognitive advantage or brain-level measurement in the cited sleep trial. | — | Small, short industry-funded trial with mixed sleep endpoints; insufficient basis for a routine form preference. Hausenblas et al.. |
| Magnesium taurate | Magnesium bound to taurine. | Comparative absorption and clinical superiority are not established by the reviewed sources. | Marketed for heart rhythm, BP, and calm because taurine has cardiovascular roles. | — | No unique cardiovascular benefit established in this evidence set. |
| Magnesium chloride | Highly soluble magnesium salt, sold as oral drops, tablets, or topical “magnesium oil.” | NIH lists chloride among forms absorbed more completely than oxide/sulfate (NIH ODS). | Oral replacement if tolerated; topical claims remain weaker than oral data. | Not systematically priced | Good soluble form; topical use should not be treated as proven systemic repletion. |
| Magnesium sulfate | Epsom salt; used medically, including IV magnesium sulfate in specific conditions, and sometimes as a laxative. | Lower oral bioavailability than soluble organic forms; NIH lists sulfate as less bioavailable than citrate/chloride/aspartate/lactate (NIH ODS). | Medical/short-term laxative uses, not routine daily supplement. | Price/availability not compared | Medical or labeled laxative use differs from daily nutritional supplementation; do not infer benefit from Epsom baths. |
| Magnesium orotate | Magnesium bound to orotic acid. | Comparative absorption is not established by the reviewed sources. | Historically studied in severe heart failure, not general wellness. | — | One manufacturer-supported severe-heart-failure study used an as-treated analysis after crossovers/exclusions. It does not justify routine wellness use. MACH trial. |
How it works
What the body does with it
Magnesium supports ATP-related energy reactions, glucose metabolism, nerve impulse conduction, muscle contraction, bone mineral structure, and the transport of calcium and potassium across cell membranes (NIH Office of Dietary Supplements). Kidneys regulate magnesium balance by lowering urinary excretion when magnesium status is low and clearing excess magnesium when kidney function is normal (NIH Office of Dietary Supplements).
Why form and delivery matter
Forms that dissolve well in liquid are generally absorbed better than poorly soluble forms, which is why citrate, chloride, lactate, and aspartate tend to outperform oxide and sulfate in NIH’s evidence summary (NIH Office of Dietary Supplements). The same property that makes unabsorbed magnesium stay in the gut also explains the laxative effect: unabsorbed salts draw water into the intestine and stimulate motility (NIH Office of Dietary Supplements).
What works and what does not
| Claimed benefit | Verdict | Evidence grade | What the evidence says | Key caveat |
|---|---|---|---|---|
| Sleep | MIXED | Weak | Small older-adult oxide/citrate trials showed mixed endpoints and low/very-low certainty. NCCIH’s January 2024 summary is not a complete newer-trial census. Mah & Pitre; NCCIH. | No reliably better low-intake responder subgroup or optimal sleep form/dose established; MgT study industry-linked. |
| Stress/anxiety | INSUFFICIENT EVIDENCE | Weak | The review found suggestive low-quality anxiety evidence, often from blends; no validated stress outcome was studied. Boyle et al.. | Do not replace therapy or prescribed medication. |
| Blood pressure | WORKS | Moderate | RCT meta-analyses show small BP reductions, not drug-level effects (Zhang et al.). | No significant treatment-effect modification by baseline status, dose/form or medicine use in the 34-trial review. |
| Constipation | WORKS | Moderate | Magnesium salts work as osmotic laxatives, and magnesium citrate has OTC laxative labeling (DailyMed magnesium citrate). | Seek medical advice with renal impairment or the labeled warnings; laxative doses differ from nutritional doses. |
| Muscle cramps | DOESN’T for typical older-adult cramps | Moderate | Cochrane concluded magnesium is unlikely to provide clinically meaningful prophylaxis for idiopathic cramps in older adults (Cochrane). | Pregnancy cramp evidence remains uncertain. |
| Migraine prevention | MAY HELP | Moderate | The 2018 review rated magnesium possibly effective (Grade C); NIH reports a separate historical 2012 probably-effective recommendation. von Luckner & Riederer; NIH ODS. | Common migraine doses can exceed the 350 mg/day supplemental UL, so use clinician guidance. |
| Blood sugar / diabetes | MIXED | Weak | Overall HOMA-IR improved in one review, while fasting glucose/HbA1c were not significantly improved; longer-duration subgroup signals were exploratory. Simental-Mendia et al.; NIH ODS. | Not a diabetes treatment replacement. |
| Bone health | MIXED | Weak | Dietary magnesium is associated with bone mineral density, but supplementation has not clearly proven fracture prevention (Groenendijk et al., Farsinejad-Marj et al.). | Observational associations cannot establish causality or an optimal supplement regimen. |
| Depression | MIXED | Weak | Recent meta-analysis of depressive disorder trials suggests improvement, but trials are heterogeneous and small (2023 meta-analysis). | Use as nutrition support, not as standalone depression care. |
Benefits by claim
Sleep: popular, plausible, but not proven for everyone
The older-adult trial enrolled 46 people with low dietary magnesium intake; 43 completed. It used 500 mg elemental magnesium as oxide daily for 8 weeks and was powered on a renin biomarker. Some insomnia measures improved, but total sleep time did not. The later three-trial review (151 participants) judged evidence low or very low certainty and did not establish a preferred salt or optimal dose (Abbasi et al., Mah & Pitre).
NCCIH’s January 2024 summary said evidence was insufficient for sleep disorders. A later 2024 MgT trial analyzed 76 adults over 3 weeks using 75 mg elemental magnesium/day: some subjective/wearable scores improved, but total sleep time, overall Oura sleep score and sleep efficiency did not differ significantly. AIDP funded the trial, three authors had AIDP affiliations and Threotech supplied Magtein (NCCIH, Hausenblas et al.).
Evidence grade: Weak. Correcting low intake is a nutritional indication; a greater insomnia response in low-intake people is not established, and no reliable bedtime dose is defined by these studies.
Stress and anxiety: suggestive but low-quality evidence
The 2017 review found suggestive but low-quality subjective-anxiety evidence in heterogeneous studies, often testing combinations. No study used a validated stress outcome, and low baseline magnesium was not shown to predict benefit. Sanofi funded the initial search and provided three unpublished studies; one author was on its Consumer Healthcare advisory board. The reported no-role statement does not remove those relationships (Boyle et al., Boyle et al.).
Evidence grade: Weak. Magnesium can be part of nutrition correction, but anxiety disorders need evidence-based mental health care.
Blood pressure: small but credible effect
A 2016 meta-analysis of 34 randomized double-blind placebo-controlled trials with 2,028 participants found small average reductions: systolic 2.00 mmHg and diastolic 1.78 mmHg. Trial doses ranged 238–960 mg/day, with median 368 mg for 3 months; study quality and outcomes varied. It did not establish a preferred salt, optimal dose or stronger effect in low-status patients or particular medicine users (Zhang et al.).
Evidence grade: Moderate. Magnesium is a helper, not a substitute for antihypertensive medication, sodium reduction, weight management, exercise, or sleep apnea treatment.
Constipation: works through osmotic laxative action
Specific magnesium salts work as osmotic laxatives. Adult magnesium oxide trials and the Japanese constipation guideline support that clinical role; they do not establish equal benefit for every salt. The DailyMed citrate liquid label covers occasional constipation, with kidney, abdominal-symptom, bowel-change, magnesium-restriction and pregnancy/breastfeeding warnings (DailyMed magnesium citrate; Magnesium oxide review; Constipation guideline).
Evidence grade: Moderate for laxative effect. This is one of the clearest uses, but it is also where misuse can cause diarrhea, dehydration, electrolyte imbalance, or hypermagnesemia in vulnerable people.
Muscle cramps: little meaningful benefit for older-adult idiopathic cramps
For idiopathic skeletal muscle cramps in older adults, Cochrane found magnesium supplementation is unlikely to provide clinically meaningful prevention (Cochrane). The same review found pregnancy-cramp evidence uncertain and less definitive (Cochrane).
Evidence grade: Moderate negative for older-adult idiopathic cramps; insufficient for pregnancy cramps.
Migraine prevention: limited prevention evidence; dose and supervision matter
NIH reports that a 2012 AAN/AHS guideline rated magnesium probably effective for migraine prevention. The separate 2018 review of five adult randomized placebo-controlled studies rated it Grade C, possibly effective. Neither establishes every salt as equally effective or a universally optimal regimen (NIH Office of Dietary Supplements, von Luckner & Riederer).
Evidence grade: Moderate. Because migraine-prevention doses often exceed 350 mg/day supplemental magnesium, this should be medically supervised.
Blood sugar and diabetes: conflicting clinical evidence
Magnesium participates in glucose metabolism, but small clinical supplementation studies are conflicting. Simental-Mendia’s review found an overall HOMA-IR improvement, not significant overall fasting glucose, HbA1c or insulin improvements; longer-duration signals were subgroup findings. The linked Chua/Cinco/Paz-Pacheco JAFES 2017 review found no significant overall glucose/HbA1c effect or low-magnesium subgroup benefit (NIH Office of Dietary Supplements, Simental-Mendía et al., Chua et al., JAFES).
Evidence grade: Weak. Correct low magnesium intake; do not treat magnesium as a glucose-lowering medicine.
Bone health: necessary nutrient, weak supplement proof
Magnesium is required for structural bone development, but supplement trials do not yet show a clear fracture-prevention outcome (NIH Office of Dietary Supplements). Systematic reviews find more support for associations between magnesium intake and bone mineral density than for proven fracture reduction (Groenendijk et al., Farsinejad-Marj et al.).
Evidence grade: Weak. Food-first adequacy is sensible; high-dose supplementation solely for bones is not well proven.
Depression: emerging but not treatment-grade evidence
The 2023 review pooled seven small trials involving 325 adults with depressive disorders and found lower symptom scores. Doses/forms, duration and co-treatment varied, including one intravenous study; heterogeneity was high and safety reporting limited. Authors declared no financial support and no commercial/financial conflicts, which does not clear every underlying trial’s finances (2023 meta-analysis).
Evidence grade: Weak. Correct deficiency or low intake, but do not delay professional depression care.
Risks and reported side effects
High magnesium intake from food is low risk for healthy people because kidneys eliminate excess magnesium, but high-dose supplemental or medicine magnesium can cause diarrhea, nausea, and abdominal cramping (NIH Office of Dietary Supplements). The adult tolerable upper intake level for supplemental/medicine magnesium is 350 mg/day; this UL does not include magnesium naturally present in food and drinks (NIH Office of Dietary Supplements). The UL is not a safety guarantee for renal impairment and does not prescribe a universal ceiling for physician-supervised treatment.
| Side effect | Frequency / likelihood | Dose relationship | Forms most associated | Mechanism | What to do |
|---|---|---|---|---|---|
| Loose stools / diarrhea | Reported with supplemental/laxative use; rates vary by study and product | Dose-related, including below the UL in susceptible people | NIH lists carbonate, chloride, gluconate and oxide commonly; citrate laxative labeling also expects bowel effects. | Unabsorbed salts draw water into the intestine and stimulate motility (NIH ODS). | Follow product or prescriber instructions; seek advice for persistent or severe symptoms. |
| Nausea and abdominal cramping | Reported at high supplemental or laxative doses; comparative rates not established | Dose-related | Citrate/oxide/hydroxide/sulfate laxative products | Osmotic bowel effect and GI irritation (NIH ODS). | Follow product or prescriber instructions; seek advice for persistent or severe symptoms. |
| Laxative effect | Expected for citrate, hydroxide, oxide, sulfate laxative dosing | Intentional with OTC laxative doses | Citrate, oxide, hydroxide, sulfate | Osmotic water retention in bowel | Use short term unless clinician advises otherwise. |
| Low blood pressure, flushing, lethargy, weakness | Rare in healthy adults at normal doses; more likely with toxicity | Risk rises with very high doses, renal impairment, antacids/laxatives | Any magnesium salt if dose is excessive | Elevated serum magnesium depresses neuromuscular and cardiovascular function (NIH ODS). | Stop and seek medical care if severe. |
| Hypermagnesemia / magnesium toxicity | Rare but serious | NIH describes toxicity with very large laxative/antacid intakes, often >5,000 mg elemental/day; this is not a minimum toxic dose. Kidney impairment increases risk. | Any high-dose product, especially laxatives/antacids | Kidneys cannot clear excess magnesium; serum magnesium rises | Emergency care for confusion, severe weakness, breathing difficulty, irregular heartbeat, or collapse. |
| Cardiac arrest / respiratory depression | Very rare but life-threatening | Extreme overdose or impaired renal clearance | Any high-dose magnesium source | Severe hypermagnesemia can impair conduction and neuromuscular function (NCBI Bookshelf StatPearls). | Emergency medical care. |
Selected interactions and precautions
Some medicines bind magnesium in the gut; others change magnesium losses or retention. Product-specific labels give different spacing rules. Small BP or glucose meta-analysis effects do not establish a clinically important interaction with every antihypertensive or diabetes drug. Ask a clinician/pharmacist about the specific product, timing and renal risk NIH ODS; BP review.
| Interacts with | Type | Severity | Mechanism | Action | Source |
|---|---|---|---|---|---|
| Oral bisphosphonates: alendronate, risedronate, ibandronate | Medication | Moderate | Magnesium-rich supplements/medicines decrease bisphosphonate absorption. | Take magnesium at least 2 hours before or after oral bisphosphonates. This is NIH’s general summary; follow the specific medicine label or pharmacist advice because intervals can differ. | NIH ODS |
| Tetracycline antibiotics: doxycycline, tetracycline, minocycline, demeclocycline | Medication | High | Magnesium forms insoluble complexes that reduce antibiotic absorption. | Take antibiotic at least 2 hours before or 4–6 hours after magnesium. This is NIH’s general summary; follow the specific medicine label or pharmacist advice because intervals can differ. | NIH ODS |
| Quinolone/fluoroquinolone antibiotics: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin | Medication | High | Chelation lowers antibiotic absorption and may risk treatment failure. | Take antibiotic at least 2 hours before or 4–6 hours after magnesium. This is NIH’s general summary; follow the specific medicine label or pharmacist advice because intervals can differ. | NIH ODS |
| Loop diuretics: furosemide, bumetanide | Medication | Moderate | Chronic use increases urinary magnesium loss. | Monitor magnesium status if long-term use, cramps, arrhythmia risk, or low potassium. | NIH ODS |
| Thiazide diuretics: hydrochlorothiazide, chlorthalidone, indapamide | Medication | Moderate | Chronic use can increase urinary magnesium loss. | Monitor electrolytes; do not self-correct high doses without labs. | NIH ODS |
| Potassium-sparing diuretics: amiloride, spironolactone | Medication | Moderate | These reduce magnesium excretion and may raise magnesium retention. | Use cautiously, especially with kidney disease or high-dose supplements. | NIH ODS |
| Proton pump inhibitors: omeprazole, pantoprazole, esomeprazole, lansoprazole | Medication | Moderate | Long-term PPI use can cause hypomagnesemia, sometimes not corrected until PPI is stopped. | Consider serum magnesium before and during long-term use. | NIH ODS |
| Levothyroxine | Medication | Moderate | A 15-person healthy-volunteer crossover found reduced thyroxine exposure with dissolved magnesium aspartate; citrate reduction was not significant. It did not test hypothyroid clinical outcomes or 4 hour spacing. | Follow the levothyroxine tablet label: at least 4 hours before/after absorption-interfering drugs. Ask about the specific magnesium product and monitoring. | ThyroMag crossover trial; Current tablet label |
| Gabapentin | Medication | Moderate | Magnesium/aluminum antacids reduce gabapentin absorption. | Take gabapentin at least 2 hours AFTER the magnesium/aluminum antacid. The label does not establish the same effect for every nutritional magnesium salt. | FDA gabapentin label |
| Eltrombopag | Medication | High | Polyvalent cations including magnesium reduce eltrombopag absorption. | Take eltrombopag at least 2 hours before or 4 hours after magnesium/minerals. | DailyMed eltrombopag label |
| Mycophenolate mofetil | Medication | Moderate–High | Magnesium/aluminum antacids can decrease mycophenolic acid exposure. | Use clinician-directed separation; DailyMed advises antacids at least 2 hours after mycophenolate. | DailyMed mycophenolate label |
| ACE inhibitors: lisinopril, enalapril, ramipril | Medication | Use caution | The reviewed evidence does not establish a specific interaction with every named drug. Magnesium caused small average BP changes; renal impairment can independently increase magnesium toxicity risk. | Follow the prescribed BP/renal monitoring plan; discuss new supplements or laxatives if symptomatic or kidney function is impaired. | NIH ODS safety framework |
| ARBs: losartan, telmisartan, valsartan | Medication | Use caution | The reviewed evidence does not establish a specific interaction with every named drug. Magnesium caused small average BP changes; renal impairment can independently increase magnesium toxicity risk. | Follow the prescribed BP/renal monitoring plan; discuss new supplements or laxatives if symptomatic or kidney function is impaired. | BP meta-analysis; NIH ODS |
| Other antihypertensives: calcium-channel blockers, beta-blockers, alpha-blockers, nitrates | Medication | Use caution | The reviewed evidence does not establish a specific interaction with every named drug. Magnesium caused small average BP changes; renal impairment can independently increase magnesium toxicity risk. | Follow the prescribed BP/renal monitoring plan; discuss new supplements or laxatives if symptomatic or kidney function is impaired. | Zhang et al. |
| Antidiabetic medicines: insulin, sulfonylureas, metformin, GLP-1 drugs, SGLT2 inhibitors | Medication | Individual clinical review | The cited reviews do not establish a hypoglycemia interaction with each listed medicine; overall glucose/HbA1c effects were largely null or conflicting. | Continue prescribed diabetes care and monitoring; assess magnesium replacement separately when clinically indicated. | Simental-Mendía et al.; NIH ODS |
| Chronic kidney disease or reduced eGFR | Condition | Avoid unsupervised use | Reduced renal clearance increases risk of hypermagnesemia and toxicity. | Use only with clinician guidance and labs. | NIH ODS; NCBI Bookshelf |
| GI disease or malabsorption: Crohn’s disease, celiac disease, chronic diarrhea, intestinal surgery | Condition | Monitor | These conditions can reduce magnesium absorption or increase losses. | Assess status clinically; supplement only as part of a medical plan. | NIH ODS |
| Older age | Condition | Monitor | Older adults are more likely to have lower intake, reduced absorption, higher urinary losses, and interacting medication use. | Prefer food-first correction and low-dose supplements unless prescribed. | NIH ODS |
| Calcium supplements | Supplement | No universal spacing rule established | The reviewed guidance does not establish universal absorption competition requiring 2 hour separation. The magnesium oxide review warns of milk-alkali syndrome with excess calcium/alkali, which is a different issue. | Review total doses, renal function and combined antacid/laxative use; no routine two-hour rule is established here. | NIH ODS; Magnesium oxide review |
| Iron supplements | Supplement | Product-specific advice | Magnesium oxide can affect iron through adsorption/pH in the narrative review; the NIH guidance does not establish a universal nutritional Mg/iron separation interval. | Ask about the actual iron and magnesium formulation, especially when treating deficiency or also taking absorption-sensitive medicines. | NIH ODS; Magnesium oxide review |
| Zinc supplements | Supplement | Moderate at high zinc doses | Very high zinc intake, 142 mg/day, can interfere with magnesium absorption and disrupt magnesium balance. | Avoid chronic high-dose zinc unless medically prescribed. | NIH ODS |
| Alcohol heavy use | Substance / condition | Moderate | Alcohol use disorder is a risk group for magnesium inadequacy. | Assess diet and labs; do not rely only on supplements. | NIH ODS |
| Neuromuscular blockers / IV magnesium context | Medication context | Medical supervision only | High magnesium can enhance neuromuscular blockade and depress respiration. | Relevant mainly in hospital/IV settings, not routine low-dose supplements. | NCBI Bookshelf Hypermagnesemia |
Who should avoid magnesium
Kidney impairment raises magnesium toxicity risk, particularly with large or repeated laxative/antacid doses. Obtain product-specific medical advice for renal disease, unexplained abdominal symptoms or bowel obstruction concerns. The citrate liquid laxative label specifically lists kidney disease, abdominal pain/nausea/vomiting, persistent bowel-habit change, magnesium restriction and pregnancy/breastfeeding as reasons to ask a clinician; these are not identical contraindications for every nutritional magnesium product (DailyMed magnesium citrate; NIH ODS; Hypermagnesemia reference).
Doses and eligibility differ by age, pregnancy/lactation, renal function and medicine use. Supplemental/medicine ULs are 65 mg/day at ages 1–3,110 mg at 4–8 and 350 mg at 9–18 and adults; no infant UL is established. Food magnesium is excluded. These nutritional limits do not replace an individual clinician-supervised treatment plan (NIH Office of Dietary Supplements).
Dosage and how to take magnesium
US adult RDAs are 400–420 mg/day for men and 310–320 mg/day for women from total intake, varying with age. The adult 350 mg/day supplemental/medicine UL excludes food/drink and principally reflects GI adverse-effect risk; it is not an optimal supplement dose, a safety guarantee, or a universal limit on physician-supervised treatment (NIH Office of Dietary Supplements, NIH Office of Dietary Supplements).
| Goal | Evidence / dosing basis | Form evidence | Timing | Notes |
|---|---|---|---|---|
| General intake gap | Replace an identified intake gap; no universal 100–200 mg requirement | Choose dose/product and tolerance individually; no universal salt winner | Follow product directions and medicine-specific spacing | Count supplemental/medicine sources toward the adult 350 mg UL; supervised treatment may differ. NIH ODS. |
| Sleep support | No established optimal sleep dose in the reviewed evidence | Older trials: oxide/citrate; short MgT trial industry-linked | No universal bedtime schedule established | Weak/low-certainty evidence; assess persistent insomnia rather than escalating for sedation. Older-adult review. |
| Constipation | Product-label laxative dosing | Citrate, oxide, hydroxide-type laxative products | Usually with a full glass of water | Use short term; avoid in kidney disease unless supervised (DailyMed magnesium citrate). |
| Blood pressure support | Trials 238–960 mg/day; median 368 mg/day for 3 months | No preferred form or optimal dose established | Clinical use and schedule require an individual plan | Small average BP effect; higher-than-UL dosing requires medical supervision. Zhang et al.. |
| Migraine prevention | The 2018 review discusses 600 mg/day; no universal optimum | Use a clinician-selected studied product; not all salts proved equivalent | Follow the prescribed schedule; no universal timing rule established | Doses may exceed UL; use clinician supervision (NIH ODS). |
| Muscle cramps | Not routinely recommended | None preferred | Not applicable | Cochrane evidence does not support routine use for older-adult idiopathic cramps (Cochrane). |
Infographics with full text versions
Infographic 1: Magnesium forms head-to-head
Text version of infographic 1
| Form | Absorption | Clinical role / limits | Verdict |
|---|---|---|---|
| Glycinate/bisglycinate | No unique advantage established here | Intake replacement if indicated | No proven universal tolerance winner |
| Citrate | Better than oxide in small studies | Supplement or specific labeled laxative | No price/value ranking established |
| Oxide | Lower than citrate | Clinically studied osmotic laxative | Absorption and laxative benefit differ |
| Threonate | Not compared as clinical absorption winner | Preliminary sleep study | Industry-funded; mixed endpoints |
| Chloride | More completely absorbed than oxide/sulfate | Oral intake replacement if indicated | Topical systemic benefit not established here |
| Malate/taurate/orotate | Comparative evidence uncertain here | Unique claims not established | MACH orotate study manufacturer-supported |
| Sulfate | Lower oral absorption in NIH summary | Medical or labeled laxative use | Route and product directions matter |
Infographic 2: Evidence strength by claimed benefit
Text version of infographic 2
- Specific clinical uses: osmotic laxatives for constipation and small average BP reduction. Migraine prevention has limited, possibly-effective evidence and may need supervised doses.
- Mixed/weak evidence: sleep, blood sugar, bone health, depression.
- Anxiety evidence is low quality and validated stress outcomes were not studied; older-adult idiopathic cramps show little meaningful prevention benefit.
Infographic 3: Dosing by goal
Text version of infographic 3
| Goal | Dose | Form | Caution |
|---|---|---|---|
| Daily intake gap | Replace an identified intake gap | Individual product/dose/tolerance | Adult 350 mg supplemental/medicine UL; supervised treatment may differ |
| Sleep support | No established optimal sleep dose | No established preferred salt | Low-certainty and mixed endpoints; review. |
| Constipation | Use product-label laxative dosing | Citrate/oxide/hydroxide | Avoid in kidney disease unless supervised |
| Blood pressure | Trial doses vary | No optimal salt/dose established | Monitor BP and medications |
| Migraine prevention | The 2018 review discusses 600 mg/day | Clinician-directed | May exceed 350 mg/day UL |
| Adult supplemental UL | 350 mg/day | All supplemental/medicine forms | Food/drink excluded; not a renal-safety guarantee |
Infographic 4: Interaction matrix
Text version of infographic 4
- Separate doses: follow the exact antibiotic/bisphosphonate or levothyroxine label. Eltrombopag needs spacing from polyvalent cations; gabapentin and mycophenolate label examples concern magnesium/aluminum antacids, not every nutritional Mg salt.
- Monitor status: loop diuretics, thiazide diuretics, long-term proton pump inhibitors, alcohol use disorder, and diabetes-related magnesium losses.
- Use caution: potassium-sparing diuretics can increase magnesium retention. BP/renal monitoring may be appropriate with other medicines, but the reviewed trials do not establish a specific interaction with every antihypertensive.
- Avoid self-prescribing: kidney disease, severe dehydration, bowel obstruction symptoms, unexplained abdominal pain, and high-dose laxative use.
- Main mechanisms: chelation in the gut, altered kidney excretion, additive blood pressure effects, and neuromuscular effects at toxic levels.
Infographic 5: Food-first magnesium sources
Text version of infographic 5
| Food | Serving | Magnesium | Percent DV |
|---|---|---|---|
| Pumpkin seeds, roasted | 1 ounce | 156 mg | 37% |
| Chia seeds | 1 ounce | 111 mg | 26% |
| Almonds, dry roasted | 1 ounce | 80 mg | 19% |
| Spinach, boiled | 1/2 cup | 78 mg | 19% |
| Cashews, dry roasted | 1 ounce | 74 mg | 18% |
| Black beans, cooked | 1/2 cup | 60 mg | 14% |
| Brown rice, cooked | 1/2 cup | 42 mg | 10% |
Values are from the NIH ODS magnesium food-source table (NIH Office of Dietary Supplements).
Related research
For deeper, evidence-graded context on the conditions magnesium is most often used for, see Pure City Research's condition guides:
- Sleep: prevention and management guide
- High blood pressure: prevention and management guide
- Stress, anxiety & depression: prevention and management guide
Frequently asked questions
Does magnesium glycinate help you sleep?
The cited older-adult insomnia review tested oxide/citrate and found low/very-low-certainty evidence; it did not establish glycinate as a superior sleep form or an optimal sleep dose. Correcting low intake is a separate nutritional goal, not a proven marker of greater insomnia benefit. NCCIH’s January 2024 summary predates the later MgT trial (Mah & Pitre, NCCIH).
Which magnesium is best: glycinate or citrate?
No universal winner or best GI tolerance is established by the reviewed evidence. Citrate has better small-study absorption evidence than oxide and a separate labeled laxative role; absorption alone does not prove better sleep or general health outcomes. Choose an indicated elemental dose and individual product/tolerance rather than the marketing name (Lindberg et al., NIH ODS; Citrate laxative label).
Can I take magnesium citrate daily?
A nutritional supplement and citrate liquid laxative are different regimens. The label reviewed here is for occasional constipation and advises clinician review when laxatives are needed for more than a week or specified kidney/abdominal/bowel warnings apply. A dose below the population UL does not guarantee safety for every renal condition or medicine combination (DailyMed magnesium citrate).
Is magnesium oxide useless?
Magnesium oxide absorbs less completely than citrate or chloride in the NIH summary, but its osmotic laxative action has adult constipation trial support. Lower nutrient absorption does not mean no clinical use. The reviewed evidence does not establish a universal cheapest product or maximum-absorption clinical winner (NIH Office of Dietary Supplements; Magnesium oxide review; Constipation guideline).
Can magnesium stop muscle cramps?
For typical idiopathic muscle cramps in older adults, the best evidence says probably not. A Cochrane review concluded magnesium is unlikely to provide clinically meaningful cramp prevention in older adults, while pregnancy-cramp evidence remains uncertain (Cochrane).
How much magnesium is too much?
For adults, the tolerable upper intake level is 350 mg/day from supplements or medicines; magnesium naturally present in food does not count toward that UL. High-dose supplements and laxatives can cause diarrhea, nausea, cramping, and rare hypermagnesemia, especially in kidney disease (NIH Office of Dietary Supplements). The UL is not a sharp toxicity threshold or a safety guarantee; physician-supervised treatment may use different doses.
Which magnesium is best for Indians?
The clinical studies reviewed here do not establish a country-specific best magnesium salt or compare current Indian availability and prices. For an actual nutritional gap, use applicable local guidance and a correctly labeled elemental dose; kidney function, medicines and individual tolerance matter. The US intake figures elsewhere in this article should not be assumed to be Indian recommendations US NIH guidance.
Can I take magnesium with antibiotics or thyroid medicine?
NIH’s general antibiotic summary is at least 2 hours before or 4–6 hours after magnesium, but exact medicine-label intervals can differ. A small ThyroMag trial tested simultaneous dissolved citrate/aspartate with levothyroxine in healthy volunteers, not 4 hour separation. Levothyroxine tablet labeling separately advises at least 4 hours from absorption-interfering drugs; ask about the exact product and monitoring (NIH Office of Dietary Supplements, PubMed levothyroxine-magnesium trial; Levothyroxine tablet label).
Sources and funding notes
Research funding at a glance
10 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
- NIH Office of Dietary Supplements. Magnesium — Health Professional Fact Sheet. U.S. government source; source country: United States; public guidance; complete page-author disclosures and every underlying-study financial chain are not supplied. Source
- NCCIH. In the News: Magnesium Supplements for Sleep Disorders. January 2024 U.S. NIH guidance, predating the later MgT trial; full underlying-study finances were not traced. Source
- Lindberg JS, Zobitz MM, Poindexter JR, Pak CYC. Magnesium bioavailability from magnesium citrate and magnesium oxide. Journal of the American College of Nutrition. NIH grants from NIDDK, NIAMS and NCRR indexed. Original abstract and grant record read; complete full-paper conflicts and product terms not recovered. Source
- Walker AF et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnesium Research. Lamberts Healthcare manufactured/donated supplements; the Swiss International Foundation for Promotion of Nutrition Research and Nutrition Education provided top-up funding. Complete author conflicts, cash amounts and ultimate foundation backers not reported. Outlier exclusions affected absorption significance; no defecation-frequency difference found. Source
- Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA. Bioavailability of magnesium food supplements: A systematic review. 2021. Original abstract and declaration read: no known financial/personal conflicts declared. Full review methods, cash funding and underlying-study finances remain unrecovered. Research record
- Abbasi B et al. The effect of magnesium supplementation on primary insomnia in elderly. Journal of Research in Medical Sciences. Shahid Beheshti university nutrition institute financial support; no conflicts declared. Product purchase/donation terms not reported. Trial used 500 mg elemental oxide; 43 of 46 older participants completed. Source
- Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. No specific review grant; named Canadian graduate/institutional support including CGS-M, Dalhousie Killam and Research Nova Scotia. No competing interests declared; underlying trials not fully financially traced. Source
- Hausenblas HA et al. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems. Sleep Medicine: X. Funded by AIDP Inc.; three authors had AIDP affiliations/study roles; Threotech manufactured and supplied Magtein. Exact cash/material terms not stated; mixed endpoints in 76 analyzed participants over 3 weeks at 75 mg elemental/day. Source
- Zhang X et al. Effects of Magnesium Supplementation on Blood Pressure. Hypertension. IU Health–IU School of Medicine Strategic Research Initiative support; authors declared no conflicts. Accepted original manuscript read; all 34 underlying trial financial chains not exhaustively traced. Source
- Simental-Mendía LE et al. Effects of oral magnesium supplementation on insulin sensitivity and glucose control. Pharmacological Research. Original abstract read: overall HOMA-IR benefit, not significant overall glucose/HbA1c/insulin benefit. Full funding/conflict/procurement declarations not recovered. Source
- Garrison SR et al. Magnesium for skeletal muscle cramps. Cochrane Database of Systematic Reviews. CIHR stipend, NIHR infrastructure, MRC centre and Motor Neurone Disease Association support; author Garrison wrote an included trial and did not rate its bias. One included trial reported active manufacturer involvement; all trial finances not fully traced. Source
- von Luckner A, Riederer F. Magnesium in migraine prophylaxis — is there an evidence-based rationale? Headache. Original abstract rates magnesium Grade C, possibly effective. Complete original funding, conflicts and included-trial product terms not recovered. Source
- Groenendijk I et al. Impact of magnesium on bone health in older adults. Bone. Jaap Schouten Foundation grant JSF_SU_17_8 indexed. Original abstract and grant record read; full paper methods/conflicts and ultimate foundation financing not recovered. Source
- Farsinejad-Marj M et al. Dietary magnesium intake, bone mineral density and risk of fracture. Osteoporosis International. Publisher acknowledges Isfahan University Food Security Research Center financial support; grant 54545 indexed. Publisher states conflicts: none. Full subscription methods and all underlying-study finances not recovered. Source
- Boyle NB et al. The effects of magnesium supplementation on subjective anxiety and stress. Nutrients. Sanofi funded the initial systematic search and provided three unpublished studies; one author disclosed Sanofi Consumer Healthcare advisory board membership; source country: United Kingdom. Source
- 2023 meta-analysis. Magnesium supplementation beneficially affects depression in adults with depressive disorder. Frontiers in Psychiatry. Authors declared no financial support and no commercial/financial conflicts; this does not clear the finances of all seven included trials. Source
- DailyMed. Magnesium citrate liquid label. Manufacturer-submitted Drug Facts, distributed by CDMA Quality Choice and manufactured by Nice-Pak. NLM hosts labeling; it is not independent comparative research. Source
- NCBI Bookshelf / StatPearls. Hypermagnesemia. Privately published StatPearls chapter hosted by NLM. Cascella/Vaqar declared no relevant financial relationships with ineligible companies; chapter-specific cash financing not stated. Source
- Chua FB, Cinco JE, Paz-Pacheco E. Magnesium supplementation and glycemic control: JAFES 2017 review, indexed 2021. Funding: none/no conflicts declared; underlying trial finance not fully traced. Original source
- Magnesium oxide in constipation: 2021 original clinical/safety review. AMED/JSPS support and multiple pharmaceutical author relationships. Original source
- Japanese chronic constipation guideline 2023, English 2025 publication. Strong/evidence A osmotic laxative recommendation; committee industry ties and incomplete cash-finance detail. Original source
- Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure, republished 2009. Woerwag Pharma support; small as-treated analysis with crossovers/exclusions. Original source
- ThyroMag 2025 crossover PK study: 15 healthy volunteers, dissolved magnesium aspartate/citrate plus levothyroxine tablets. No specific funding/conflicts declared; exact product terms unreported. Original source
- Levothyroxine tablet product labeling: absorption-interfering drug spacing and monitoring. Manufacturer labeling hosted by NLM. Original source
- Gabapentin product labeling: magnesium/aluminum antacid interaction; not an all-nutritional-Mg-salt comparison. Original source
- Eltrombopag product labeling: polyvalent-cation administration precautions. Original source
- Mycophenolate product labeling: magnesium/aluminum hydroxide antacid absorption precautions. Original source
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
